GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Additional Paid-In Capital

Evolus (FRA:EVL) Additional Paid-In Capital : €575.8 Mil(As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Evolus Additional Paid-In Capital?


Evolus's quarterly additional paid-in capital increased from Sep. 2024 (€548.9 Mil) to Dec. 2024 (€588.1 Mil) but then stayed the same from Dec. 2024 (€588.1 Mil) to Mar. 2025 (€575.8 Mil).

Evolus's annual additional paid-in capital increased from Dec. 2022 (€487.2 Mil) to Dec. 2023 (€494.0 Mil) and increased from Dec. 2023 (€494.0 Mil) to Dec. 2024 (€588.1 Mil).

Evolus Additional Paid-In Capital Historical Data

The historical data trend for Evolus's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Additional Paid-In Capital Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 249.16 446.71 487.23 494.00 588.11

Evolus Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 543.80 560.51 548.88 588.11 575.84

Evolus Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Evolus Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Evolus's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Additional Paid-In Capital
Comparable Companies
NIKA ELTP ETON AKBA TLRY SIGA ZYBT ORGO AVDL EBS ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
EOLS:USA EVL:Germany
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Website
https://www.evolus.com
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines